icon-folder.gif   Conference Reports for NATAP  
  The Liver Meeting
Digital Experience
November 13 - 16 - 2020
Back grey_arrow_rt.gif
Combination Treatment With Cilofexor and Firsocostat Normalizes Cell Death Marker Cytokeratin 18 in Patients With Advanced Fibrosis Due to NASH
  AASLD 2020 Nov 11-16
Kris V. Kowdley,1 Anita Kohli,2 Aasim M. Sheikh,3 Bal Bhandari,4 Jen-Chieh Chuang,5 Andrew Billin,5 Scott D. Patterson,5 Eliza Harting,5 Catherine Jia,5 Ryan S. Huss,5 Robert P. Myers,5 Keyur Patel,6 Heidi Kabler,7 Peter J. Ruane,8 Simone I. Strasser,9 Vincent Wong,10 Naim Alkhouri,11 Rohit Loomba,12 Mazen Noureddin13
1Liver Institute Northwest and Washington State University, Seattle, WA; 2Arizona Liver Health, Chandler, AZ; 3GI Specialists of Georgia, Marietta; 4Delta Research Partners, LLC, Bastrop, LA; 5Gilead Sciences, Inc., Foster City, CA; 6Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; 7MountainView Hospital, Las Vegas, NV; 8Ruane Medical & Liver Health Institute, Los Angeles, CA; 9Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; 10The Chinese University of Hong Kong, People's Republic of China; 11Texas Liver Institute, UT Health San Antonio, TX; 12UC San Diego NAFLD Research Center, La Jolla, CA; 13Cedars-Sinai Fatty Liver Program, Los Angeles







References: 1. Brenner C, et al. J Hepatol 2013;59:583-94; 2. Feldstein AE, et al. Hepatology 2009;50:1072-8; 3. Loomba R, et al. EASL 2020, abstr LBO04